| Cash Flow | 2025-09-30 |
|---|---|
| Net income (loss) | -1,274,502 |
| Changes in derivative liability | 675,528 |
| Increase (decrease) in interest expense attributable to amortization of discount | 52,148 |
| Common stock issued for expenses | 128,100 |
| (increase) decrease in accounts receivable | 110,000 |
| (increase) decrease in prepaid expenses | -47,562 |
| Increase (decrease) in accounts payable | 821 |
| Increase (decrease) in accrued expenses | 173,312 |
| Increase (decrease) in penalties | 50,000 |
| Increase (decrease) in unearned income | -126,560 |
| Net cash provided by (used in) operating activities | -383,591 |
| Increase (decrease) in convertible notes payable | 194,599 |
| Increase (decrease) other liabilities | 50,000 |
| Common stock issued for cash | 58,200 |
| Borrowings from notes payable to related parties | 149,631 |
| Net cash provided by (used in) financing activities | 452,430 |
| Net increase (decrease) in cash | 68,839 |
| Cash and cash equivalents at beginning of period | 716 |
| Cash and cash equivalents at end of period | 69,555 |
Regen BioPharma Inc (RGBPP)
Regen BioPharma Inc (RGBPP)